1. Home
  2. REVB vs DRMA Comparison

REVB vs DRMA Comparison

Compare REVB & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

N/A

Current Price

$1.28

Market Cap

5.1M

Sector

Health Care

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$1.32

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REVB
DRMA
Founded
2020
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REVB
DRMA
Price
$1.28
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
115.5K
2.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.59
52 Week High
$3.73
$7.33

Technical Indicators

Market Signals
Indicator
REVB
DRMA
Relative Strength Index (RSI) 47.54 44.44
Support Level $0.77 $0.63
Resistance Level $1.38 $2.29
Average True Range (ATR) 0.09 0.16
MACD -0.03 0.03
Stochastic Oscillator 31.03 18.60

Price Performance

Historical Comparison
REVB
DRMA

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Share on Social Networks: